What do federal, provincial, and territorial agencies review regarding new medications?

• A. To decide if the new medication will be included in public drug plans and under what terms.
• B. To approve clinical trial endpoints.
• C. To set manufacturing standards for production.
• D. To regulate pharmacy operating hours.

Answer: (A)

The main concept is how public funding decisions for new medications are made. Federal, provincial, and territorial agencies review whether a new drug should be funded by public drug plans and, if so, under what terms. This involves assessing the drug’s value, budget impact, and appropriate access criteria, and then determining formulary placement and reimbursement conditions. In Canada, after regulatory approval for safety and effectiveness, HTA bodies (like CADTH) evaluate the drug’s value, and price negotiations (often through the pan-Canadian Pharmaceutical Alliance) set the terms for coverage by public plans.

Why the other ideas don’t fit: approving clinical trial endpoints happens during drug development and regulatory review; setting manufacturing standards is about production quality and GMP compliance; regulating pharmacy operating hours is unrelated to decisions about funding or coverage of new medications.